1-4 of 4
Tolga Sutlu
Close
Sort by
Journal Articles

CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion

Hareth Nahi, Michael Chrobook, Stephan Meinke, Charlotte Gran, Nicole Marquardt, Gabriel Afram, Tolga Sutlu, Mari Gilljam, Birgitta Stellan, Arnika Kathleen Wagner, Lilian Walther-Jallow, Johan Liwing, Monika Klimkowska, Goesta Gahrton, Per Ljungman, Hans-Gustaf Ljunggren, Evren Alici
Journal: Blood
Blood (2021) 138 (Supplement 1): 4796.
https://doi.org/10.1182/blood-2021-152522
Published: 2021
Journal Articles

The Prognostic Significance of 8p21 Deletion in Multiple Myeloma

Hareth Nahi, Tolga Sutlu, Evren Alici, Goesta Gahrton, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 5153.
https://doi.org/10.1182/blood.V112.11.5153.5153
Published: 2008
Journal Articles

Impact of Chromosome 13 Deletion and Plasma Cell Load on Long-Term Survival of Patients with Multiple Myeloma Undergoing Autologous Transplantation

Esbjörn Paul, Tolga Sutlu, Evren Alici, Goesta Gahrton, MD, PhD, Hareth Nahi
Journal: Blood
Blood (2008) 112 (11): 5148.
https://doi.org/10.1182/blood.V112.11.5148.5148
Published: 2008
Journal Articles

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components

Evren Alici, Tolga Sutlu, Bo Björkstrand, Mari Gilljam, Birgitta Stellan, Hareth Nahi, Hernan Concha Quezada, Gösta Gahrton, Hans-Gustaf Ljunggren, M. Sirac Dilber
Journal: Blood
Blood (2008) 111 (6): 3155–3162.
https://doi.org/10.1182/blood-2007-09-110312
Published: 2008
Includes: Supplemental data